BioSpace News Archive

Alex Hamlow has joined Seno Medical Instruments, Inc. as Chief Revenue Officer. Seno Medical is the leader in improving the process of diagnosing breast cancer and the pioneer of the Imagio® Breast Imaging System with opto-acoustic/ultrasound (OA/US) imaging technology.

Skye Bioscience, Inc. (OTCQB: SKYED) (“Skye” or the “Company”), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes

Bionano Genomics, Inc. announced that on September 18, 2023, the Compensation Committee of the Company’s Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 106,000 shares of common stock to Gülsen Kama, the Company’s new Chief Financial Officer, under the Company’s 2020 Inducement Plan, as amended.

Galmed Pharmaceuticals Ltd. announced that the Company received a letter from the Nasdaq Listing Qualifications, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.

Invitae announced that it received a notice from the New York Stock Exchange on September 20, 2023, indicating the company is not currently in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company’s common stock over a consecutive 30 trading-day period was less than $1.00 per share.

Shanghai Henlius Biotech, Inc. announced that the new drug application for new indication of HANSIZHUANG in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic ESCC, has been approved by the NMPA, providing a new treatment option for patients with ESCC.

Asha Therapeutics announced today that it has been selected as a BLUE KNIGHT™ company.

The Board of Directors of GE HealthCare Technologies Inc., a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2023 payable on November 15, 2023 to all shareholders of record as of October 20, 2023.

Kestra Medical Technologies is launching the ASSURE Clinician Experience (ACE), a program that lets electrophysiology and cardiology professionals wear and simulate use of the ASSURE® Wearable Cardioverter Defibrillator (WCD) system at The Heart Rhythm Society #HRX2023 global health and technology conference, September 21-23, 2023 in Seattle, WA.

Brandon Cuevas has been selected as executive vice president for Kaiser Foundation Health Plan with national accountability for health plan strategy, capabilities, and operations, effective October 1, 2023.